A Case of Multidrug-Resistant Klebsiella pneumoniae Treated with Carrimycin

One of the most pressing emerging issues in bacterial resistance is multidrug-resistant Klebsiella pneumoniae. The treatment of K. pneumoniae infections is often problematic because of the lack of available therapeutic options, leading to negative effects on morbidity, mortality, and healthcare-associated costs. Carrimycin is a macrolide antibiotic with good antibacterial effects. In this study, we report a patient diagnosed with multidrug-resistant K. pneumoniae infection who was treated with carrimycin. The patient presented with cough, expectoration, dyspnea, and severe hypoxemia requiring noninvasive ventilation. We successively used a variety of antibiotics, including meropenem, tigecycline, and polymyxin, with unsatisfactory results. Finally, we used carrimycin, and the patient's condition improved, resulting in hospital discharge. Therefore, for patients with multidrug-resistant K. pneumoniae infection that does not respond to conventional anti-infective treatments, carrimycin can be considered a treatment option.

Automated summary

One of the urgent issues in bacterial resistance is multidrug-resistant Klebsiella pneumoniae. The lack of available therapeutic options for K. pneumoniae infections leads to negative effects on morbidity, mortality, and healthcare costs. Carrimycin, a macrolide antibiotic, showed effective treatment of a patient with multidrug-resistant K. pneumoniae infection. When other antibiotics failed to bring satisfactory results, carrimycin improved the patient's condition and led to hospital discharge. Therefore, carrimycin can be considered as a treatment option for multidrug-resistant K. pneumoniae infections that do not respond to conventional anti-infective treatments.